2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The diagnosis of depression, a frequent comorbidity of chronic obstructive pulmonary disease (COPD), is often supported by questionnaires, such as the Patient Health Questionnaire 9 (PHQ-9). It is unknown to which extent its single questions are affected by the clinical characteristics of COPD patients.

          We addressed this question in 2255 GOLD grade 1–4 patients from the COSYCONET ( COPD and Systemic Consequences - Comorbidities Network) COPD cohort. The dependence on COPD severity was assessed using symptoms, exacerbation risk (GOLD A-D; modified Medical Research Council dyspnoea scale (mMRC)), and frequent comorbidities as predictors of PHQ-9 results, while including age, gender, body mass index (BMI) and smoking habits as covariates.

          Symptoms and exacerbation risk were associated with depression in an additive manner, with mean elevations in the PHQ-9 sum score by 2.75 and 1.44 points, respectively. Asthma, sleep apnoea, gastrointestinal disorders, osteoporosis and arthritis were linked to increases by 0.8 to 1.3 points. Overall, the COPD characteristics contributed to the mean PHQ-9 score by increases from 4.5 or 5.2 to 6.3 points, respectively, when either taking GOLD A as reference or the absence of comorbidities. This finding was independent of the diagnosis of mental disorder or the intake of antidepressants. The presence of COPD led to an increase in the proportion of scores indicating depression from 12 to 22%. Single item analysis revealed homogenous effects regarding GOLD groups, but heterogeneous effects regarding GOLD grades.

          These findings indicate specific effects of COPD severity on the PHQ-9 depression score, especially symptoms and exacerbation risk, explaining the high prevalence of depression in COPD. Alternative explanations like an overlap of COPD severity and PHQ-9 items are discussed. Of note, we also found COPD treatment effects on depression scores.

          Electronic supplementary material

          The online version of this article (10.1186/s12931-019-0997-y) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

          This Executive Summary of the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include: (i) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; (ii) for each of the groups A to D, escalation strategies for pharmacological treatments are proposed; (iii) the concept of de-escalation of therapy is introduced in the treatment assessment scheme; (iv)non-pharmacological therapies are comprehensively presented and (v) the importance of co-morbid conditions in managing COPD is reviewed.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            [Prevalence of depressive symptoms and diagnosed depression among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)].

            In the German Health Interview and Examination Survey (DEGS1), current depressive symptoms were assessed with the "Patient Health Questionnaire" (PHQ-9) in a representative population-based sample of 7,988 adults 18-79 years old. In addition, previously diagnosed depression was assessed by physician interview. The prevalence of current depressive symptoms (PHQ-9 ≥ 10 points) is 8.1 % (women: 10.2 %; men: 6.1 %). For both sexes, the prevalence is highest among 18- to 29-year-olds and decreases with age. Persons with higher socioeconomic status (SES) are less likely to have current depressive symptoms. The lifetime prevalence of diagnosed depression is 11.6 % (women: 15.4 %; men: 7.8 %) and is highest among persons 60-69 years old. The 12 month prevalence is 6.0 % (women: 8.1 %; men: 3.8 %) and is highest among 50- to 59-year-olds. In women, but not in men, prevalences decrease with increasing SES. The results describe the distribution of two important aspects of depression among the adult population in Germany and confirm previously observed associations with age, gender and SES. An English full-text version of this article is available at SpringerLink as supplemental.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              How robust is the association between smoking and depression in adults? A meta-analysis using linear mixed-effects models.

              Our objective was to use meta-analytic techniques to assess the strength of the overall relationship and role of potential moderators in the association between smoking and depression in adults.
                Bookmark

                Author and article information

                Contributors
                Kathrin.Kahnert@med.uni-muenchen.de
                Journal
                Respir Res
                Respir. Res
                Respiratory Research
                BioMed Central (London )
                1465-9921
                1465-993X
                11 February 2019
                11 February 2019
                2019
                : 20
                : 30
                Affiliations
                [1 ]ISNI 0000 0004 1936 973X, GRID grid.5252.0, Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Comprehensive Pneumology Center Munich (CPC-M), , Ludwig-Maximilians-Universität München, ; Ziemssenstr. 1, 80336 Munich, Germany
                [2 ]ISNI 0000 0004 1936 973X, GRID grid.5252.0, Department of Internal Medicine V, , University of Munich (LMU), ; Ziemssenstr. 1, 80336 Munich, Germany
                [3 ]ISNI 0000 0004 1936 9756, GRID grid.10253.35, Department of Medicine, Pulmonary and Critical Care Medicine, , University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany, Member of the German Center for Lung Research (DZL), ; Baldingerstrasse, 35043 Marburg, Germany
                [4 ]Institute of Health Economics and Health Care Management, Helmholtz Zentrum München GmbH – German Research Center for Environmental Health, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research, Ingolstädter Landstr. 1, 85764 Munich, Germany
                [5 ]ISNI 0000 0004 1936 9756, GRID grid.10253.35, ASCONET Study Coordination Office, , University of Marburg, ; Baldingerstraße, 35043 Marburg, Germany
                [6 ]ISNI 0000 0000 9529 9877, GRID grid.10423.34, Department of Pneumology, , Hannover Medical School, ; Carl-Neuberg-Str. 1, 30625 Hannover, Germany
                [7 ]Pulmonary Research Institute at LungenClinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research, Woehrendamm 80, 22927 Grosshansdorf, Germany
                [8 ]GRID grid.411937.9, Department of Internal Medicine V – Pulmonology, Allergology, Respiratory Intensive Care Medicine, , Saarland University Hospital, ; Kirrberger Straße 1, 66424 Homburg, Germany
                [9 ]ISNI 0000 0004 1936 9756, GRID grid.10253.35, Department of Clinical Psychology and Psychotherapy, , Philipps-University Marburg, Germany, ; Gutenbergstraße 18, 35032 Marburg, Germany
                Article
                997
                10.1186/s12931-019-0997-y
                6371561
                30744630
                a56aacad-6bab-452b-b077-4494fc86e7a3
                © The Author(s). 2019

                Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 17 December 2018
                : 4 February 2019
                Funding
                Funded by: German Federal Ministry of Education and Research
                Award ID: 01 GI 0881
                Funded by: AstraZeneca GmbH
                Award ID: not applicable
                Funded by: Bayer Schering Pharma AG
                Award ID: not applicable
                Funded by: Boehringer Ingelheim Pharma GmbH & Co. KG
                Award ID: not applicable
                Funded by: Chiesi GmbH
                Award ID: not applicable
                Funded by: GlaxoSmithKline
                Award ID: not applicable
                Funded by: Grifols Deutschland GmbH
                Award ID: not applicable
                Funded by: MSD Sharp & Dohme GmbH
                Award ID: not applicable
                Funded by: Mundipharma GmbH
                Award ID: not applicable
                Funded by: Novartis Deutschland GmbH
                Award ID: not applicable
                Funded by: Pfizer Pharma GmbH
                Award ID: not applicable
                Funded by: Takeda Pharma Vertrieb GmbH & Co
                Award ID: not applicable
                Categories
                Research
                Custom metadata
                © The Author(s) 2019

                Respiratory medicine
                copd,depression,phq-9
                Respiratory medicine
                copd, depression, phq-9

                Comments

                Comment on this article